Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study

Table 3 Local-regional progression-free survival in 120 stage IV NSCLC patients according to radiotherapy dose

Cycle	Dose (Gy)	No.	Survival rate (%)				Median survival (months)	95% confidence interval		χ ²	p
Cycle	Dose (Gy)	No.	1 year	2 year	3 year	5 year	Median survival (months)	95% confidence interval		χ ²	p
2-3	<63	23	41.7	27.8	20.9	0	10	5.5	14.5	0.040	0.842
2-3	≥63	23	43.5	26.1	19.6	0	9	4.3	13.7	0.040	0.842
4-5	<63	18	32.6	21.7	0	0	9	6.6	11.4	9.217	0.002
4-5	≥63	56	77.4	36.2	27.2	15.9	20	16.5	23.5	9.217	0.002

ISSN: 1471-2407